SCHEMBL5159936

SCHEMBL5159936

CCOC(C(=O)OC(C)(C)C)N1CCC[C@H]1C(=O)O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 1/20 0.40
HSD17B10 Q99714 3/20 0.39
LMNA P02545 2/20 0.38
CYP2C19 P33261 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.37
ACE P12821 7/20 0.36
ALDH1A1 P00352 1/20 0.36
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
REN P00797 3/20 0.35
KDM4E B2RXH2 1/20 0.35
F2 P00734 1/20 0.35
LTA4H P09960 1/20 0.35
MAPT P10636 1/20 0.35
PEPD P12955 1/20 0.35
ALOX15 P16050 1/20 0.35
PTGS1 P23219 1/20 0.35
HTR2A P28223 1/20 0.35
PTGS2 P35354 1/20 0.35
HRH1 P35367 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5163685 0.87 FKBP1A (0.41) RAB9AHSD17B10LMNASMN1; SMN2ALDH1A1
SCHEMBL9486009 0.81 RAB9A (0.42) RAB9AHSD17B10LMNACYP2C19SMN1; SMN2
SCHEMBL8823436 0.72 RAB9A (0.35) RAB9AHSD17B10LMNACYP2C19SMN1; SMN2
SCHEMBL7398963 0.72 ACE (0.39) RAB9AHSD17B10LMNACYP2C19SMN1; SMN2
SCHEMBL21371448 0.72 RAB9A (0.42) RAB9AHSD17B10LMNASMN1; SMN2ACE
SCHEMBL14104056 0.70 HSD17B10 (0.44) RAB9AHSD17B10LMNACYP2C19SMN1; SMN2
SCHEMBL17053427 0.70 HSD17B10 (0.44) RAB9AHSD17B10LMNACYP2C19ACE
SCHEMBL1955287 0.69 ACE (0.45) RAB9AHSD17B10LMNACYP2C19ACE
SCHEMBL13101915 0.69 ACE (0.45) RAB9AHSD17B10LMNACYP2C19ACE
SCHEMBL10110614 0.68 RAB9A (0.43) RAB9AHSD17B10LMNACYP2C19ACE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070232601-A1 Vla-4 Inhibitor DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-10-04 US disclosed
EP-1757602-A1 VLA-4 INHIBITOR DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-02-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232601-A1 Vla-4 Inhibitor VCAM1, ITGB4, ITGA4 RAB9A 1194/4885HSD17B10 3097/4885LMNA 4162/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.